The U.S. FDA has issued an advisory recommending a lower dose for products containing the hypnotic zolpidem, such as Ambien, Ambien CR, Edluar, and Zolpimist. In Canada, zolpidem is sold under the trade name Sublinox. Dosing for Intermezzo, a zolpidem formulation for middle-of-the-night awakening, is unaffected. Subscribe to read more It takes 30 seconds or login using your email address Please enter the email address that you registered the news…
…The results of the phase III trials, CARE MS-I and CARE MS-II, show that alemtuzumab significantly reduces relapse rate by about 50% compared to interferon-beta-1a SC (Cohen et al. Lancet 2012; 380:1819-1828). Subscribe to read more It takes 30 seconds or login using your email address Please enter the email address that you registered the newsletter with Continue…
…tric in MS research is the proportion of patients who are disease-activity free (DAF), defined as no relapses, no MRI activity (T2 or Gd+ T1 lesions) and no sustained EDSS progression. One of the first uses was an analysis of the AFFIRM dataset, which reported a two-year DAF rate of 37% with natalizumab versus 7% with placebo (Havrdova et al. Lancet Neurol 2009;8:254-260). Subscribe to read more It takes 30 seconds or login using your email addres…
REPORT FROM THE AMERICAN ACADEMY OF NEUROLOGY (AAN) ANNUAL MEETING, SAN DIEGO, CA, MARCH 16-23, 2013 – TOWER is the second of three phase III studies investigating the safety and efficacy of oral teriflunomide, the active metabolite of leflunomide which acts by inhibiting dihydroorotate dehydrogenase. The drug received FDA approval in September 2012 but has not yet been approved in Canada. Subscribe to read more It takes 30 seconds or login using…
REPORT FROM THE AMERICAN ACADEMY OF NEUROLOGY (AAN) ANNUAL MEETING, SAN DIEGO, CA, MARCH 16-23, 2013 -High sodium chloride levels promote the differentiation of proinflammatory Th17 cells that are highly pathogenic, according to the preliminary results of an in vitro study in naïve human CD4+ cells (Kleinewietfeld et al. AAN 2013; abstract S11.004). Subscribe to read more It takes 30 seconds or login using your email address Please enter the emai…